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Epidemiology
An organism of worldwide prevalence,
M. pneumoniae tends to cause sporadic
illness throughout the year. In addition, in
most countries, it has been noted that the
infection rates tend to peak every 3 to 5
years as an epidemic.2
As these epidemics tended to involve
schoolchildren and military recruits, the
trend has been to associate this organism
with these younger age groups.  However,
endemic illness (occasionally even
epidemics) does occur at ALL ages. In
particular, the incidence of mycoplasma
pneumonia in the under fives seems to be
increasing in most developed countries,
possibly because of the increasing use of
day care centers for the very young. In the
elderly, it is second only to
S. pneumoniae as a cause of community
acquired pneumonia.3,4
The disease is transmitted person to
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Mycoplasma pneumoniae is best thought of as a bacterium
without a cell wall, a property that has important therapeutic
considerations. It is an exclusively human pathogen. As most
cases of human infection are either sub clinical or result in a
relatively mild infection of the respiratory tract, infections
with this organism are much more common in the community
than people generally realize.1
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with active disease are the ones most likely
to transmit the illness, the organism may
persist in the respiratory tract of
asymptomatic carriers for long periods of
time, even when these would have been
active cases treated with antibiotics.1 It is
thought that such persons serve as a
reservoir or carrier from which the disease is
maintained within the human population.
Re infection readily occurs.
The clinical illness
Apart from pneumonia, the organism is
capable of causing upper respiratory tract
infections, such as pharyngitis. Once again,
as an etiological agent of sore throats, it is
probably a much more common cause than
it is usually given credit for. While
mycoplasma infections may trigger off
bronchospasm in chronic asthmatics, more
recent evidence is suggesting that the
organism can be a primary cause in the
development of this chronic lung disease. In
the future, it shall be interesting to see if
the incidence of asthma goes up as children
are exposed to the organism at ever-
younger ages, for reasons explained above.
The pneumonic illness is typically a mild
one, and sometimes referred to as the
“walking pneumonia”.  Certainly, compared
to the classical pneumococcal pneumonia,
the onset is more gradual. Many adult
patients will have little or no symptoms, yet
physical and X-ray examination will show
very definite signs of a chest infection. The
disease tends to be more marked in
children, possibly since, on their first
encounter with the organism they would
have no form of acquired immunity to give
them at least partial protection against the
disease.5
When symptoms are severe, these would
usually be ascribed to an aggressive immune
response to the infection, rather than the
organism itself, which, with rare exceptions,
does not spread beyond the mucosal
epithelial surface.
Laboratory diagnosis
As the illness, both clinically and
radiologically, is very non-specific,
microbiological tests are essential to
confirm the diagnosis. Over the years,
various such tests have been developed:
1. Mycoplasma culture - apart from being
laborious and expensive, and relatively
insensitive6  compared to DNA
amplification techniques, there is also
the problem of the organism persisting
in the patient’s respiratory tract for (in
some cases) weeks or months after the
acute episode. With all these drawbacks,
it is not surprising to learn that most
microbiological labs would never
attempt to culture mycoplasma.
2. Antigen detection techniques - this has
been tried using many different
laboratory methodologies. Two examples
would be direct immunofluorescence7
and antigen capture enzyme
immunoassay. In these cases, the
already discussed problem of detecting
a presence of the organism in a human
carrier is compounded by the tendency
of such tests to cross react with other
non pathogenic mycoplasma which are
normally present in the human
respiratory tract. This low specificity,
together with a low sensitivity means
that they cannot really be recommended
for use, especially now that superior
molecular diagnostic techniques are
available.
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3. Molecular identification techniques -
Labeled probes that target the non-
amplified mycoplasma DNA, have been
supplanted by the superior amplified
technologies, and specifically PCR
(polymerase chain reaction).6 Its
advantages include a high specificity
(but beware the mycoplasma human
carrier!), the ability to detect the
organism’s DNA or RNA (depending on
the kit used) in preserved tissue, as well
as the short turnaround time for
completing the test and the fact that,
at least theoretically, it should give a
quicker result than an antibody test in a
positive case.
On the other hand, the PCR test may
turn negative very soon after the start of
antibiotic treatment (in some cases, within
24 hours) while the antibody test will
remain positive for a considerably longer
period of time. Thus, the result of a PCR
specimen taken after the start of antibiotic
therapy has to be interpreted with caution.
There have also been problems with false
negative results, probably from the presence
of reaction inhibitors present in the
patient’s upper respiratory tract.
At this stage, the mycoplasma PCR tests
available are still in use as a research tool,
rather than as a routine diagnostic method.
Together with cost, this renders this
technique not quite ready for widespread
use.
In the light of all of the limitations
mentioned above, it is not surprising that
antibody testing is still the most commonly
performed microbiological test to confirm
suspected mycoplasma pneumonia.
4. Serology - Antibodies to
M. pneumoniae would be expected to
reach their maximum serum
concentration 3 to 6 weeks after
exposure. Bearing in mind that most
cases of the illness would be associated
with a relatively long incubation period
(1 - 3 weeks), it can be expected that
by the time most patients present to
their doctor, an antibody response can
usually be demonstrated.
In a primary infection (most likely in
peadiatric age group), the specific IgM
antibodies would start to appear within one
week of the infection. IgG antibodies would
typically show up two weeks later.  Where
reinfection occurs (most adult cases) the
patient may show up only IgG
immunoglobulins, without ever exhibiting
an IgM response.8 On the other hand an IgM
response has occasionally been shown to
persist for months or even years following
the primary infection! This sometimes
makes the proper interpretation of the
patient’s IgM + IgG response to a
mycoplasma infection, and specifically when
it comes to distinguishing a past from a
recent infection difficult.
In the future, one other possible
diagnostic tool is the detection of a specific
IgA response, which preliminary studies
suggest might be the most reliable indicator
of a recent mycoplasma infection than both
IgG and IgM antibodies.
In view of the above, it would appear
prudent to test suspected cases both of IgG
and IgM antibodies simultaneously, and
then repeat the tests 2 to 3 weeks later to
detect any changes in titre.
Treatment
The organism is exquisitely sensitive to
the macrolides and related compounds
(azalides and ketolides), as well as the
newer respiratory quinolones. As such, it is
no surprise to find these antibiotics forming
the mainstay of treatment.
Treatment duration varies according to
the agent selected: in most cases it would
hover around the 10-day mark. However,
there are those who would insist that cases
of mycoplasma pneumonia should be treated
for at least 2 to 3 weeks.
Over the years, various antibiotics have
been successfully used to treat mycoplasma
pneumonia in the published literature.
However, one should point out that in some
of these studies, the number of patients
involved where quite small.
These have included:
• Clarithromycin and Erythromycin
for 10 or 14 days9
• Telithromycin for 7 to 10 days10
• Azithromycin for 3 or 5 days11
• Moxifloxacin for 7 to 14 days12
• Levofloxacin for 7 to 14 days13
This is not a comprehensive list of all
studies done on the subject. In fact, one
would expect all macrolides and
fluoroquinolones to be effective against M.
pneumoniae. Furthermore, tetracyclines
should also work against this organism.14
Curiously, in one small comparator
study, co-amoxiclav, together with various
other beta lactam antibiotics12,13 appeared
to achieve a very good clinical cure rate
after 7 to 14 days of treatment, despite the
fact that this antibiotic is definitely
inactive against M. pneumoniae. As
described above, most of these “walking
pneumonias” are usually mild and self-
limited, and the majority of patients can be
expected to make a full recovery even in the
absence of antibiotic treatment.
Vaccine research
Attempts to develop a
M. pneumoniae vaccine have been going on
for many years, unfortunately without
success. In a way this is not surprising,
considering that some individuals who
succumb to the infection, and develop an
immune response to the organism may still
get reinfected later on in their lives. After a
number of failures with different
experimental vaccines, interest in the
subject appears to be low at the moment.
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